Figures & data
Figure 1. (a) US representation of a benign thyroid nodule. (b) Two laser applicators have been introduced within the nodule, with a distance of ∼5 mm between the needle tips. (c) Gas bubbles in the nodule are the immediate effect of thermal ablation. (d) Immediate post-procedural CEUS shows lack of contrast enhancement in the central part of the nodule. (e) Six-month follow-up shows volumetric reduction of the ablated nodule. (f) CEUS of the ablated nodule shows shrinkage and low vascularization of the inner core of the nodule, due to cicatricial effects.
![Figure 1. (a) US representation of a benign thyroid nodule. (b) Two laser applicators have been introduced within the nodule, with a distance of ∼5 mm between the needle tips. (c) Gas bubbles in the nodule are the immediate effect of thermal ablation. (d) Immediate post-procedural CEUS shows lack of contrast enhancement in the central part of the nodule. (e) Six-month follow-up shows volumetric reduction of the ablated nodule. (f) CEUS of the ablated nodule shows shrinkage and low vascularization of the inner core of the nodule, due to cicatricial effects.](/cms/asset/34ff3a6b-94c4-4cc3-bddd-3265819d3806/ihyt_a_1622795_f0001_c.jpg)
Figure 2. (a,b) US representation of a benign thyroid nodule. (b) Two laser applicators have been introduced within the nodule, with a distance of ∼5 mm between the needle tips (arrows). (c,d) Two needles are introduced in the nodule and gently moved during the procedure according to the pull-back technique (dotted arrows). (e) Air bubbles (arrows) within the ablated nodule (black arrowheads). (f) Post-procedural CEUS confirms lack of contrast enhancement inside the ablated nodule (white arrowheads).
![Figure 2. (a,b) US representation of a benign thyroid nodule. (b) Two laser applicators have been introduced within the nodule, with a distance of ∼5 mm between the needle tips (arrows). (c,d) Two needles are introduced in the nodule and gently moved during the procedure according to the pull-back technique (dotted arrows). (e) Air bubbles (arrows) within the ablated nodule (black arrowheads). (f) Post-procedural CEUS confirms lack of contrast enhancement inside the ablated nodule (white arrowheads).](/cms/asset/25b43291-e150-4a63-8bf0-d1b7ca3f3636/ihyt_a_1622795_f0002_c.jpg)
Figure 3. (a) US representation of a benign thyroid nodule (6.4 × 4.0 × 2.8 cm) in the left thyroid lobe. (b) Prominent vascularization is confirmed at Doppler US. (c) RF applicator with 1 cm size active tip is introduced within the nodule (arrow). (d) Post-procedural US shows decreased vascularization in nodule and air bubbles as hyperechoic areas (arrows). (e) After 1 month, the size of nodule is decreased (2.2 × 3.7 × 4.5 cm). (f) Further dimensional reduction after 1 year (1.3 × 1.4 × 2.4 cm).
![Figure 3. (a) US representation of a benign thyroid nodule (6.4 × 4.0 × 2.8 cm) in the left thyroid lobe. (b) Prominent vascularization is confirmed at Doppler US. (c) RF applicator with 1 cm size active tip is introduced within the nodule (arrow). (d) Post-procedural US shows decreased vascularization in nodule and air bubbles as hyperechoic areas (arrows). (e) After 1 month, the size of nodule is decreased (2.2 × 3.7 × 4.5 cm). (f) Further dimensional reduction after 1 year (1.3 × 1.4 × 2.4 cm).](/cms/asset/571b38df-b512-4f01-b5fa-ac2173197dd6/ihyt_a_1622795_f0003_c.jpg)